Evidence map›Paper›PMID 31163668›Full record

ArticleJournal of clinical medicine2019

Extremes of Liver Transplantation for Hepatocellular Carcinoma.

Michał Grąt, Maciej Krasnodębski, Marek Krawczyk, Jan Stypułkowski, Marcin Morawski, Michał Wasilewicz, Zbigniew Lewandowski, Karolina Grąt, Waldemar Patkowski, Krzysztof Zieniewicz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Michał GrątDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-091 Warsaw, Poland. michal.grat@gmail.com.ORCID 0000-0003-3372-3072
Maciej KrasnodębskiDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-091 Warsaw, Poland. mwkrasn@gmail.com.ORCID 0000-0002-6234-615X
Marek KrawczykDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-091 Warsaw, Poland. marek.krawczyk@wum.edu.pl.
Jan StypułkowskiDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-091 Warsaw, Poland. jan.styp@gmail.com.
Marcin MorawskiDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-091 Warsaw, Poland. marcin.b.morawski@gmail.com.ORCID 0000-0002-7056-8668
Michał WasilewiczLiver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, 02-091 Warsaw, Poland. newdodo@poczta.onet.pl.ORCID 0000-0002-3678-8595
Zbigniew LewandowskiDepartment of Epidemiology and Biostatistics, Medical University of Warsaw, 3 Oczki Street, 02-007 Warsaw, Poland. zbigniew.lewandowski@wum.edu.pl.ORCID 0000-0002-9963-2723
Karolina GrątSecond Department of Clinical Radiology, Medical University of Warsaw, 02-091 Warsaw, Poland. karolina.grat@gmail.com.
Waldemar PatkowskiDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-091 Warsaw, Poland. waldemar.patkowski@gmail.com.
Krzysztof ZieniewiczDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-091 Warsaw, Poland. krzysztof.zieniewicz@wum.edu.pl.
Medical University of Warsaw · PL

Funding

Foundation for Polish Science START 2018 (032.2018
6 · The paper itself

Abstract

The aim of this retrospective observational study was to evaluate outcomes of patients with extremely advanced hepatocellular carcinoma (HCC) after liver transplantation. A total of 285 HCC patients after liver transplantation were screened for eligibility based on either intrahepatic dissemination (≥10 tumors) or macrovascular invasion. Tumor recurrence was the primary end-point. The study cohort comprised 26 patients. Median recurrence-free survival was 23.2 months with hepatitis B virus (HBV) infection (

Indexed as

alpha-fetoproteinhepatocellular carcinomaliver transplantationtumor recurrence

Identifiers

PMID31163668
PMCPMC6616997
OpenAlexW2947284514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.